Vivos Seeks FDA Approval to Start Human Trials for Breakthrough Cancer Therapy
Vivos submits FDA application for human trials of RadioGel therapy, a potential game-changer in cancer treatment. If approved, this innovative approach could offer hope and more effective options to cancer patients.
The submission of Vivos' IDE application to the FDA for human clinical trials of its RadioGel therapy could be a game-changer in cancer treatment. If approved, this innovative approach has the potential to offer more effective options to cancer patients, providing hope and a new treatment avenue for those with challenging cancer types.
